An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab,Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:

Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone

There is an equal chance to be assigned to either Group 1 or Group 2. There is a lesser chance you will be assigned to Group 3. If you are assigned to receive pomalidomide and dexamethasone only (Group 2) and your disease worsens, you may be eligible to switch to treatment Group 3.

Inclusion Criteria:
• Refractory or relapsed and refractory multiple myeloma
• Measurable disease
• Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination

Exclusion Criteria:
• Solitary bone or extramedullary plasmacytoma disease only
• Active plasma cell leukemia
Phase III
John Godwin, M.D.
BMS (Bristol-Myers Squibb)
Neysa Dagostino
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside